Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries

References

• Davis JM, Chen N. Choice of maintenance medication for schizophrenia. J Clin Psychiatry 2003;64(Suppl 16):24-33
   PubMedGoogle Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23
   PubMed Web of Science ®Google Scholar
• Haro JM, Suarez D, Novick D, et al. Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. Eur Neuropsychopharmacol 2007;17:235-44
   PubMed Web of Science ®Google Scholar
• Leucht S, Heres S. Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. J Clin Psychiatry 2006;67(Suppl 5):3-8
   PubMed Web of Science ®Google Scholar
• Nasrallah HA. The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr Scand 2007;115:260-7
   PubMed Web of Science ®Google Scholar
• Kane JM, Aguglia E, Altamura AC, et al. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol 1998;8:55–66
   PubMed Web of Science ®Google Scholar
• Schooler NR. Relapse and rehospitalization: comparing oral and depot antipsychotics. J Clin Psychiatry 2003;64(Suppl 16):14-17
   PubMed Web of Science ®Google Scholar
• Davis JM, Matalon L, Watanabe MD, et al. Depot antipsychotic drugs: Place in therapy. Drugs 1994;47:741-43
   PubMed Web of Science ®Google Scholar
• Chue P. Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic. Neuropsychiatr Dis Treat 2007;3: E-pub
   Google Scholar
• Adams CE, Fenton MK, Quraishi S, et al. Systematic meta-analysis of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 2001;179:290-9
   PubMed Web of Science ®Google Scholar
• Bhanji NH, Chouinard G, Margolese HC. A review of compliance, deport intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia. Eur Neuropsychopharmacol 2004;14:87-92
   PubMed Web of Science ®Google Scholar
• Kane JM, Eerdekens M, Lindenmayer JP, et al. Long-acting injectable risperidone: Efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003;160:1125-32
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, Eerdekens M, Karcher K, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 2003;64:1250-7
   PubMed Web of Science ®Google Scholar
• Lasser RA, Bossie CA, Gharabawi GM, et al. Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone. Eur Psychiatry 2004;19:219-25
   PubMed Web of Science ®Google Scholar
• Mohl A, Westlye S, Opjordsmoen S, et al. Long-acting risperidone in stable patients with schizoaffective disorder. J Psychopharmacol 2005;19:22-31
   PubMed Web of Science ®Google Scholar
• Olivares JM, Rodriguez-Morales A, Diels J, et al. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry 2009;24:287-96
   PubMed Web of Science ®Google Scholar
• Olivares JM, Rodriguez-Martinez A, Buron JA, et al. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia. A 12- and 24-month follow-up from the e-STAR database in Spain. Appl Health Econ Health Policy 2008;6:41-53
   PubMedGoogle Scholar
• Guy W. Clinical global impression. In: Rush AJ, eds. Handbook of Psychiatric Measures. Washington, DC: American Psychiatric Association, 2000:100-2
   Google Scholar
• Endicott J, Spitzer J, Fleiss J, et al. The Global Assessment scale: a procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976;33:766-71
   PubMed Web of Science ®Google Scholar
• Niaz OS, Haddad PM. Thirty-five months experience or risperidone long-acting injection in a UK psychiatric service including a mirror–image analysis of in-patient care. Acta Psychiatr Scand 2007;116:36-46
   PubMed Web of Science ®Google Scholar
• Young CL, Taylor DM. Health resource utilization associated with switching to risperidone long-acting injection. Acta Psychiatr Scand 2006;114:14-20
   PubMed Web of Science ®Google Scholar
• Taylor DM, Fischetti C, Sparshatt A, et al. Risperidone long-acting injection: a prospective 3-year analysis of its use in clinical practice. J Clin Psychiatry 2008; e-pub
   Google Scholar
• Taylor D. Risperidone long-acting injection in practice – more questions than answers. Acta Psychiatr Scand 2006;114:1-2
   PubMed Web of Science ®Google Scholar
• Liu-Seifert H, Adams DH, Kinon BJ. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Med 2005;3:21
   PubMed Web of Science ®Google Scholar
• Beauclair L, Chue P, McCormick J, et al. Impact of risperidone long-acting injectable on hospitalization and medication use in Canadian patients with schizophrenia. J Med Econ 2007;10:427-42
   Google Scholar
• Chue P, Llorca P, Duchesne I, Leal A, et al. Hospitalization rates in patients during long-term treatment with long-acting risperidone injection. J Applied Res 2005;5:266-74
   Google Scholar
• Taylor D, Fischetti C, Sparshatt A, et al. Risperidone long-acting injection: a 6-year mirror-image study of healthcare resource use. Acta Psychiatr Scand 2009 E-pub
   Google Scholar